CliffBio
small molecule

TADALAFIL

TADALAFIL

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameTADALAFIL
Active ingredientTADALAFIL
Strength2.5MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2019
Marketing statusRX

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

TADALAFIL patent cliff — loss of exclusivity — | CliffBio